My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

82.52 -0.57 (-0.69%)

Streaming Delayed Price Updated: 1:29 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter ↗

July 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 13, 2023

We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.

Via InvestorPlace

Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive ↗

July 06, 2023

JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,

Via Benzinga

Expert Ratings for Protagonist Therapeutics ↗

July 06, 2023

Via Benzinga

Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

July 06, 2023

Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...

Via Benzinga

Where Protagonist Therapeutics Stands With Analysts ↗

June 12, 2023

Via Benzinga

Chart Of The Day: Protagonist Therapeutics - Wide Opinions ↗

June 09, 2023

Via Talk Markets

Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment ↗

July 05, 2023

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 04, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 03, 2023

Via Benzinga

Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 03, 2023

Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.

Via Benzinga

Protagonist Therapeutics: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday ↗

July 03, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...

Via Benzinga

US Stocks Mixed; Dow Falls Over 50 Points ↗

July 03, 2023

U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%...

Via Benzinga

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment ↗

May 12, 2023

Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of

Via Benzinga

Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm ↗

May 05, 2023

The company is targeting psoriasis with a first-ever mechanism that could rival leaders.

Via Investor's Business Daily

4 Analysts Have This to Say About Protagonist Therapeutics ↗

April 27, 2023

Via Benzinga

Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study ↗

March 15, 2023

Via Benzinga

Why Protagonist Therapeutics Shares Are Trading Higher Today ↗

March 07, 2023

Via Benzinga

Why Shares of Protagonist Therapeutics Rose This Week ↗

April 20, 2023

The company's lead pipeline candidate is making news.

Via The Motley Fool

Why Protagonist Therapeutics Shares Are Nosediving ↗

April 05, 2023

Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 05, 2023

Via Benzinga

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 07, 2023

Via Benzinga

Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 07, 2023

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...

Via Benzinga

Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday ↗

March 07, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Top 5 Health Care Stocks That May Collapse In February ↗

February 13, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Protagonist Therapeutics Earnings Perspective: Return On Capital Employed ↗

August 25, 2022

Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 05, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.

Via Benzinga

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.